Pulmonary arterial hypertension is characterized by perivascular and systemic inflammation. The gut microbiome influences the host immune system. Here we review the emerging preclinical and clinical evidence that strongly suggests that alterations in the gut microbiome may either initiate or facilitate progression of established pulmonary arterial hypertension by modifying the systemic immune responses. We also briefly review the relationship between the gut microbiome and preeclampsia, a vascular disease also characterized by inflammation. Key words: Dysbiosis, Right ventricle, Inflammation.

Cardiovascular Division Department of Medicine University of Minnesota Minneapolis Minnesota USA

Zobrazit více v PubMed

Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. doi: 10.1136/bmj.j5492. PubMed DOI PMC

Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T, et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry. J Am Heart Assoc. 2022;11:e024969. doi: 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1181. PubMed DOI PMC

Anand V, Roy SS, Archer SL, Weir EK, Garg SK, Duval S, Thenappan T. Trends and outcomes of pulmonary arterial hypertension-related hospitalizations in the United States: Analysis of the nationwide inpatient sample database from 2001 through 2012. JAMA Cardiol. 2016;1:1021–1029. doi: 10.1001/jamacardio.2016.3591. PubMed DOI

Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M, Investigators ST. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388:1478–1490. doi: 10.1056/NEJMoa2213558. PubMed DOI

Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175. doi: 10.1161/CIRCRESAHA.113.301141. PubMed DOI PMC

Thenappan T, Prins KW, Pritzker MR, Scandurra J, Volmers K, Weir EK. The critical role of pulmonary arterial compliance in pulmonary hypertension. Ann Am Thorac Soc. 2016;13:276–284. doi: 10.1513/AnnalsATS.201509-599FR. PubMed DOI PMC

Thenappan T, Chan SY, Weir EK. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2018;315:H1322–H1331. doi: 10.1152/ajpheart.00136.2018. PubMed DOI PMC

Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–927. doi: 10.1161/CIRCULATIONAHA.109.933762. PubMed DOI

Prins KW, Archer SL, Pritzker M, Rose L, Weir EK, Sharma A, Thenappan T. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant. 2018;37:376–384. doi: 10.1016/j.healun.2017.08.011. PubMed DOI PMC

Ormiston ML, Chang C, Long LL, Soon E, Jones D, Machado R, Treacy C, Toshner MR, Campbell K, et al. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation. 2012;126:1099–1109. doi: 10.1161/CIRCULATIONAHA.112.110619. PubMed DOI

Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res. 2011;109:867–879. doi: 10.1161/CIRCRESAHA.110.236927. PubMed DOI PMC

Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, Bhutani T, Liao W. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15:73. doi: 10.1186/s12967-017-1175-y. PubMed DOI PMC

Liu Z, Liu HY, Zhou H, Zhan Q, Lai W, Zeng Q, Ren H, Xu D. Moderate-intensity exercise affects gut microbiome composition and influences cardiac function in myocardial infarction mice. Front Microbiol. 2017;8:1687. doi: 10.3389/fmicb.2017.01687. PubMed DOI PMC

Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nat Rev Genet. 2017;18:690–699. doi: 10.1038/nrg.2017.63. PubMed DOI

Bretler T, Weisberg H, Koren O, Neuman H. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med. 2019;17:112. doi: 10.1186/s12916-019-1346-1. PubMed DOI PMC

Cresci GA, Bawden E. Gut microbiome: What we do and don't know. Nutr Clin Pract. 2015;30:734–746. doi: 10.1177/0884533615609899. PubMed DOI PMC

Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. New England J Med. 2016;375:2369–2379. doi: 10.1056/NEJMra1600266. PubMed DOI

Mokkala K, Roytio H, Munukka E, Pietila S, Ekblad U, Ronnemaa T, Eerola E, Laiho A, Laitinen K. Gut microbiota richness and composition and dietary intake of overweight pregnant women are related to serum zonulin concentration, a marker for intestinal permeability. J Nutr. 2016;146:1694–1700. doi: 10.3945/jn.116.235358. PubMed DOI

Castro A, Bemer V, Nobrega A, Coutinho A, Truffa-Bachi P. Administration to mouse of endotoxin from gram-negative bacteria leads to activation and apoptosis of T lymphocytes. Eur J Immunol. 1998;28:488–495. doi: 10.1002/(SICI)1521-4141(199802)28:02<488::AID-IMMU488>3.0.CO;2-R. PubMed DOI

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119. doi: 10.1016/B978-0-12-800100-4.00003-9. PubMed DOI

Yuille S, Reichardt N, Panda S, Dunbar H, Mulder IE. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS One. 2018;13:e0201073. doi: 10.1371/journal.pone.0201073. PubMed DOI PMC

Tan Y, Sheng Z, Zhou P, Liu C, Zhao H, Song L, Li J, Zhou J, Chen Y, Wang L, Qian H, Sun Z, Qiao S, Xu B, Gao R, Yan H. Plasma trimethylamine N-oxide as a novel biomarker for plaque rupture in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2019;12:e007281. doi: 10.1161/CIRCINTERVENTIONS.118.007281. PubMed DOI

Moutsoglou DM, Tatah J, Prisco SZ, Prins KW, Staley C, Lopez S, Blake M, Teigen L, Kazmirczak F, Weir EK, Kabage AJ, Guan W, Khoruts A, Thenappan T. Pulmonary Arterial hypertension patients have a proinflammatory gut microbiome and altered circulating microbial metabolites. Am J Respir Crit Care Med. 2023;207:740–756. doi: 10.1164/rccm.202203-0490OC. PubMed DOI PMC

Kim S, Rigatto K, Gazzana MB, Knorst MM, Richards EM, Pepine CJ, Raizada MK. Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 2020;75:1063–1071. doi: 10.1161/HYPERTENSIONAHA.119.14294. PubMed DOI PMC

Yang Y, Zeng Q, Gao J, Yang B, Zhou J, Li K, Li L, Wang A, Li X, Liu Z, Luo Q, Zhao Z, Liu B, Xue J, Jiang X, Konerman MC, Zheng L, Xiong C. High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. Eur Heart J Open. 2022;2:oeac021. doi: 10.1093/ehjopen/oeac021. PubMed DOI PMC

Yang Y, Yang B, Li X, Xue L, Liu B, Liang Y, Zhao Z, Luo Q, Liu Z, Zeng Q, Xiong C. Higher circulating Trimethylamine N-oxide levels are associated with worse severity and prognosis in pulmonary hypertension: a cohort study. Respir Res. 2022;23:344. doi: 10.1186/s12931-022-02282-5. PubMed DOI PMC

Callejo M, Mondejar-Parreno G, Barreira B, Izquierdo-Garcia JL, Morales-Cano D, Esquivel-Ruiz S, Moreno L, Cogolludo A, Duarte J, Perez-Vizcaino F. Pulmonary arterial hypertension affects the rat gut microbiome. Sci Rep. 2018;8:9681. doi: 10.1038/s41598-018-27682-w. PubMed DOI PMC

Sanada TJ, Hosomi K, Shoji H, Park J, Naito A, Ikubo Y, Yanagisawa A, Kobayashi T, Miwa H, Suda R, Sakao S, Mizuguchi K, Kunisawa J, Tanabe N, Tatsumi K. Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model. Pulm Circ. 2020;10:2045894020929147. doi: 10.1177/2045894020929147. PubMed DOI PMC

Karoor V, Strassheim D, Sullivan T, Verin A, Umapathy NS, Dempsey EC, Frank DN, Stenmark KR, Gerasimovskaya E. The short-chain fatty acid butyrate attenuates pulmonary vascular remodeling and inflammation in hypoxia-induced pulmonary hypertension. Int J Mol Sci. 2021;22:9916. doi: 10.3390/ijms22189916. PubMed DOI PMC

Huang Y, Lin F, Tang R, Bao C, Zhou Q, Ye K, Shen Y, Liu C, Hong C, Yang K, Tang H, Wang J, Lu W, Wang T. Gut Microbial Metabolite Trimethylamine. Am J Respir Cell Mol Biol. 2022;66:452–460. doi: 10.1165/rcmb.2021-0414OC. PubMed DOI

Thenappan T, Goel A, Marsboom G, Fang YH, Toth PT, Zhang HJ, Kajimoto H, Hong Z, Paul J, Wietholt C, Pogoriler J, Piao L, Rehman J, Archer SL. A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med. 2011;183:1080–1091. doi: 10.1164/rccm.201008-1303OC. PubMed DOI PMC

Ranchoux B, Bigorgne A, Hautefort A, Girerd B, Sitbon O, Montani D, Humbert M, Tcherakian C, Perros F. Gut-Lung Connection in Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2017;56:402–405. doi: 10.1165/rcmb.2015-0404LE. PubMed DOI

Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, Libert JM, Mougeot C, Moreau R, Mazmanian M, Humbert M, Herve P. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med. 2002;166:514–517. doi: 10.1164/rccm.200201-027OC. PubMed DOI

Lin KY, Chen H, Yu L. Pulmonary arterial hypertension caused by congenital extrahepatic portocaval shunt: a case report. BMC Cardiovasc Disord. 2019;19:141. doi: 10.1186/s12872-019-1124-1. PubMed DOI PMC

Iida T, Ogura Y, Doi H, Yagi S, Kanazawa H, Imai H, Sakamoto S, Okamoto S, Uemoto S. Successful treatment of pulmonary hypertension secondary to congenital extrahepatic portocaval shunts (Abernethy type 2) by living donor liver transplantation after surgical shunt ligation. Transpl Int. 2010;23:105–109. doi: 10.1111/j.1432-2277.2009.00964.x. PubMed DOI

Tatah JH, Weir EK, Prins KW, Thenappan T. A case report of portopulmonary hypertension precipitated by transjugular intrahepatic portosystemic shunt. Chest. 2021;159:e193–e196. doi: 10.1016/j.chest.2020.11.014. PubMed DOI PMC

Chesne J, Danger R, Botturi K, Reynaud-Gaubert M, Mussot S, Stern M, Danner-Boucher I, Mornex JF, Pison C, Dromer C, Kessler R, Dahan M, Brugiere O, Le Pavec J, Perros F, Humbert M, Gomez C, Brouard S, Magnan A, Consortium C. Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. PLoS One. 2014;9:e109291. doi: 10.1371/journal.pone.0109291. PubMed DOI PMC

Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, Trembath RC, Loyd JE. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801899. doi: 10.1183/13993003.01899-2018. PubMed DOI PMC

Soon E, Crosby A, Southwood M, Yang P, Tajsic T, Toshner M, Appleby S, Shanahan CM, Bloch KD, Pepke-Zaba J, Upton P, Morrell NW. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192:859–872. doi: 10.1164/rccm.201408-1509OC. PubMed DOI PMC

Zhang C, Xi Y, Zhang Y, He P, Su X, Li Y, Zhang M, Liu H, Yu X, Shi Y. Causal effects between gut microbiota and pulmonary arterial hypertension: A bidirectional Mendelian randomization study. Heart Lung. 2024;64:189–197. doi: 10.1016/j.hrtlng.2024.01.002. PubMed DOI

Huang Y, Lin F, Tang R, Bao C, Zhou Q, Ye K, Shen Y, Liu C, Hong C, Yang K, Tang H, Wang J, Lu W, Wang T. Gut microbial metabolite trimethylamine N-oxide aggravates pulmonary hypertension. Am J Respir Cell Mol Biol. 2022 doi: 10.1165/rcmb.2021-0414OC. PubMed DOI

Prisco SZ, Eklund M, Moutsoglou DM, Prisco AR, Khoruts A, Weir EK, Thenappan T, Prins KW. Intermittent fasting enhances right ventricular function in preclinical pulmonary arterial hypertension. J Am Heart Assoc. 2021;10:e022722. doi: 10.1161/JAHA.121.022722. PubMed DOI PMC

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin Infect Dis. 2018;66:e1–e48. doi: 10.1093/cid/cix1085. PubMed DOI PMC

Quagliariello A, Del Chierico F, Reddel S, Russo A, Onetti Muda A, D'Argenio P, Angelino G, Romeo EF, Dall'Oglio L, De Angelis P, Putignani L All The Other Fmt Opbg Committee Collaborators. Fecal microbiota transplant in two ulcerative colitis pediatric cases: gut microbiota and clinical course correlations. Microorganisms. 2020:8. doi: 10.3390/microorganisms8101486. PubMed DOI PMC

Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595–602. doi: 10.1126/science.abf3363. PubMed DOI PMC

Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–609. doi: 10.1126/science.abb5920. PubMed DOI

Jama HA, Rhys-Jones D, Nakai M, Yao CK, Climie RE, Sata Y, Anderson D, et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial. Nat Cardiovasc Res. 2023;2:35–43. doi: 10.1038/s44161-022-00197-4. PubMed DOI

Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52:873–880. doi: 10.1161/HYPERTENSIONAHA.108.117358. PubMed DOI

Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124:1094–1112. doi: 10.1161/CIRCRESAHA.118.313276. PubMed DOI

Kell DB, Kenny LC. A Dormant microbial component in the development of preeclampsia. Front Med (Lausanne) 2016;3:60. doi: 10.3389/fmed.2016.00060. PubMed DOI PMC

Liu J, Yang H, Yin Z, Jiang X, Zhong H, Qiu D, Zhu F, Li R. Remodeling of the gut microbiota and structural shifts in Preeclampsia patients in South China. Eur J Clin Microbiol Infect Dis. 2017;36:713–719. doi: 10.1007/s10096-016-2853-z. PubMed DOI

Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M, Group ST. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension. 2016;68:974–981. doi: 10.1161/HYPERTENSIONAHA.116.07910. PubMed DOI

Li P, Wang H, Guo L, Gou X, Chen G, Lin D, Fan D, Guo X, Liu Z. Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. BMC Med. 2022;20:443. doi: 10.1186/s12916-022-02657-x. PubMed DOI PMC